ATLANTA, GA--(Marketwire - June 30, 2008) - AtheroGenics, Inc. (NASDAQ: AGIX), today reported that it received a Staff Determination Letter from the NASDAQ Listing Qualifications Department indicating that the Company has not regained compliance with the $1.00 per share bid price requirement for continued listing set forth in Marketplace Rule 4450(b)(4). As a result, shares of the Company’s common stock are subject to delisting unless it requests a hearing before a NASDAQ Listing Qualifications Panel (the “Panel”).
